Key Points Joshua B Cohen sold 138,167 shares for a total transaction value of ~$1.9 million on Jan. 15 and Jan. 16, 2026, at a weighted average price of $13.59 per share. This sale represented 3.93% of Cohen's direct holdings at the time, reducing his direct position from 3,517,632 to 3,379,465 shares. These 10 stocks could mint the next wave of millionaires › On Jan. 15 and Jan. 16, 2026, Joshua...
Key Points Joshua B Cohen sold 138,167 shares for a total transaction value of ~$1.9 million on Jan. 15 and Jan. 16, 2026, at a weighted average price of $13.59 per share. This sale represented 3.93% of Cohen's direct holdings at the time, reducing his direct position from 3,517,632 to 3,379,465 shares. These 10 stocks could mint the next wave of millionaires › On Jan. 15 and Jan. 16, 2026, Joshua B Cohen, Co-Chief Executive Officer of Amylyx Pharmaceuticals (NASDAQ:AMLX), executed an exercise of 200,000 stock options and sold 138,167 shares in open-market transactions for a total consideration of approximately $1.9 million, according to the SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 138,167 Transaction value $1.9 million Post-transaction shares (direct) 3,379,465 Post-transaction value (direct ownership) $48.33 million Transaction value based on SEC Form 4 weighted average purchase price ($13.59); post-transaction value based on Jan. 16, 2026 market close ($14.30). Key questions How does the size of this transaction compare to Cohen’s historical selling activity? The 138,167 shares sold in this event are significantly larger than Cohen's historical median sell size of 15,220 shares since September 2024, representing an outlier primarily due to the option exercise and expiration context. The 138,167 shares sold in this event are significantly larger than Cohen's historical median sell size of 15,220 shares since September 2024, representing an outlier primarily due to the option exercise and expiration context. How did the sale affect Cohen’s direct ownership stake in Amylyx Pharmaceuticals? The transaction reduced Cohen’s direct holdings by 3.93%, leaving him with 3,379,465 shares, which equated to an estimated 4.07% insider ownership as of the filing date. Company overview Metric Value *Price $14.29 Market capitalization $1.57 billion Net income (TTM) -$149.28 million *1-year price change 313% * Price and 1-year performance calculated...